Asia
Biopharma companies are continuously working to test new treatments to the market. Here are three clinical updates announced this week, spanning three different continents.
Researchers identified a 19-nucleotide- long RNA sequence found in the SARS-CoV-2’s furin cleavage site that matched a 19-nucleotide sequence in a genetic segment owned by Moderna.
Biopharma and life sciences companies from across the globe provide updates on their businesses and pipelines.
By the end of the CREDIT-1 study, patients experienced a significant reduction in low-density lipoprotein cholesterol compared to the placebo group.
BioSpace learned that growing functional organs may indeed be possible, and about the role of protein-to-protein interactions in cancer immunotherapy.
Moderna announced plans to expand in Asia with the opening of four new subsidiaries in Malaysia, Taiwan, Singapore and Hong Kong.
The unspoken challenge is: how diverse can a trial run in the United States really be right now?
The fund will be used to target partnerships with promising early-stage biotechnology to enhance Fujifilm’s life sciences portfolio.
The FDA’s Oncologic Drugs Advisory Committee (ODAC) has recommended 14-1 that the two companies conduct a trial applicable to the U.S. population.
It’s uncertain if the origins of COVID-19 will ever be determined, but the current top theories split about evenly between a lab leak from the Wuhan Institute of Virology and a natural evolution from bats to animals to humans at a Wuhan “wet market.”
PRESS RELEASES